Compare LEDS & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEDS | INAB |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5M | 11.8M |
| IPO Year | 2010 | 2020 |
| Metric | LEDS | INAB |
|---|---|---|
| Price | $2.33 | $1.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 17.1K | ★ 36.4K |
| Earning Date | 04-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.12 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $43,009,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $105.00 | ★ N/A |
| Revenue Growth | ★ 729.81 | N/A |
| 52 Week Low | $1.01 | $0.88 |
| 52 Week High | $3.62 | $2.73 |
| Indicator | LEDS | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 58.19 | 45.67 |
| Support Level | $1.76 | $0.96 |
| Resistance Level | $2.47 | $1.22 |
| Average True Range (ATR) | 0.13 | 0.06 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 97.56 | 23.81 |
SemiLEDs Corp develops, manufactures, and sells light-emitting diode chips and LED components. The company's products include LED Chips, LED Components, and Lighting Products. Its products are used for general lighting applications, including street lights and commercial, industrial, system, and residential lighting; specialty industrial applications, such as ultraviolet, or Ultraviolet, curing of polymers, LED light therapy in medical/cosmetic applications, counterfeit detection, LED lighting for horticulture applications, architectural lighting and entertainment lighting. Substantial revenue is generated from the sale of LED components products. Geographically, it derives a majority of its revenue from Japan.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.